← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV24행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 2
high dose (ZM-02, ZM-02 (high dose))
Zhongmou Therapeutics·Retinitis Pigmentosa (RP)
62 trials
Overview
Program
ZM-02 (high dose)
Overview
Company
Zhongmou Therapeutics
Overview
Modality
CGT
Overview
Target
Retinitis Pigmentosa (RP)
Overview
Indication
Retinitis Pigmentosa (RP)
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
Technology
Vector
AAV-F capsid gene therapy rescues disease pathology in a model of pyruvate dehydrog
MoA
Mechanism
targets (Lingo-1, NMDA receptor
MoA
Biomarker
EGFR) signaling resulting from long-term high
PK/PD
Species
Mouse
PK/PD
Animal (cat.)
Mouse, In vitro
PK/PD
Experiment
Pharmacokinetic
Toxicology
Species
Mouse
Toxicology
Animal (cat.)
Mouse, In vitro
Toxicology
Major finding
Efficacy and safety of procedural sedation-analgesia during laser photocoagulation for retinopathy of prematurity: a systematic review.. Laser photocoagulation for retinopathy of prematurity (ROP) in preterm infants causes significant procedural pain. Although general anaesthesia (GA) is the standard of care, many settings frequently rely on inadequate sedation-analgesia or topical anaesthesia alo…
Clinical
Safety signal
Efficacy and safety of procedural sedation-analgesia during laser photocoagulation for retinopathy of prematurity: a systematic review.. Laser photocoagulation for retinopathy of prematurity (ROP) in preterm infants causes significant procedural pain. Although general anaesthesia (GA) is the standard of care, many settings frequently rely on inadequate sedation-analgesia or topical anaesthesia alo…
Clinical
Result source
ClinicalTrials.gov NCT02208037
Clinical
Program phase
PHASE_2
Clinical
Trial ref
NCT02208037